Improving physical function in older breast cancer survivors using senolytics
Using Senolytics to Improve Physical Function in Older Breast Cancer Survivors
This study is looking at how a special treatment called senolytics might help older women who have survived breast cancer feel stronger and improve their physical abilities by getting rid of old, damaged cells in their bodies.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10757042 on NIH RePORTER |
What this research studies
This research investigates how senolytics, which are agents that selectively eliminate senescent cells, can help improve physical function in older women who have survived breast cancer. After cancer treatment, many survivors experience significant declines in their physical abilities due to damage in multiple body systems. The study aims to target the aging processes that contribute to these declines, particularly focusing on the harmful effects of senescent cells. By potentially reducing these cells, the research hopes to restore physical function and enhance the quality of life for these patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are older women who have survived breast cancer and are experiencing declines in physical function post-treatment.
Not a fit: Patients who are not breast cancer survivors or those who do not experience physical function decline may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve physical function and quality of life for older breast cancer survivors.
How similar studies have performed: Previous research has shown promise in using senolytics to alleviate frailty in older adults, suggesting that this approach may be effective in this context as well.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Sedrak, Mina S — University of California Los Angeles
- Study coordinator: Sedrak, Mina S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.